Invivyd Inc. (IVVD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Invivyd Inc. (IVVD) has a cash flow conversion efficiency ratio of -0.205x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.71 Million) by net assets ($203.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Invivyd Inc. (IVVD) balance sheet quality index to measure how much of total assets are equity-financed.
Invivyd Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore IVVD operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Invivyd Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invivyd Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ugro Capital Limited
NSE:UGROCAP
|
0.007x |
|
CVW CleanTech Inc
V:CVW
|
-0.006x |
|
Ibraco Bhd
KLSE:5084
|
0.021x |
|
Namyong Terminal PCL
BK:NYT
|
0.085x |
|
Origin Property PCL
BK:ORI
|
0.023x |
|
Surya Fajar Capital Tbk PT
JK:SFAN
|
-0.027x |
|
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
|
0.041x |
|
Centrum Medyczne ENEL-MED SA
WAR:ENE
|
0.238x |
Annual Cash Flow Conversion Efficiency for Invivyd Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Invivyd Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Invivyd Inc. (IVVD) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $241.54 Million | $-58.13 Million | -0.241x | +90.47% |
| 2024-12-31 | $67.54 Million | $-170.49 Million | -2.524x | -158.71% |
| 2023-12-31 | $177.47 Million | $-173.16 Million | -0.976x | -57.89% |
| 2022-12-31 | $355.97 Million | $-219.99 Million | -0.618x | -86.67% |
| 2021-12-31 | $558.02 Million | $-184.74 Million | -0.331x | -248.25% |
| 2020-12-31 | $-65.25 Million | $-14.57 Million | 0.223x | -- |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more